Drugs / CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
also known as
UCD19 CAR-T
Cell therapy targets CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04544592 | Mar 2021 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia | University of Colorado, Denver | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04544592 ↗ |
| Known as | UCD19 CAR-T | “We hypothesize that CD19-directed CAR-T cells manufactured using the Miltenyi CliniMACs Prodigy System (UCD19 CAR-T) will be safe, well-tolerated, and show preliminary efficacy...” NCT04544592 ↗ |
| Modality | Cell therapy | “This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally” NCT04544592 ↗ |
| Target | CD19 | “The CD19 CAR used in this study consists of three main components” NCT04544592 ↗ |